Intended Use

Software intended to aid clinicians in identifying individuals with Left Ventricular Ejection Fraction (LVEF) ≤ 40% from ECG and heart sounds in patients at risk for heart failure, including those with coronary artery disease, diabetes, cardiomyopathy, hypertension, and obesity; for use in adults 18 years or older.

Technology

The device uses machine learning algorithms and signal processing to analyze ECG and phonocardiogram signals collected by FDA-cleared Eko Stethoscopes, processing data via a web-based API with deep convolutional neural networks to classify LVEF ≤ 40%; it outputs likelihood notifications for clinical referral, not diagnostic confirmation.

Performance

Performance validation was conducted on a proprietary database with 3,456 paired ECG and heart sound recordings, validated against gold standard echocardiogram measurements. Sensitivity was 74.7% and specificity 77.5% for detecting LVEF ≤ 40%. Testing included significant demographic variation analysis and software verification per IEC 62304 standards.

Predicate Devices

No predicate devices specified

Ready to Sharpen Your Edge?

Subscribe to join 7,600+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.